NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

NOVN.CH

123.06

+1.75%↑

LONN.CH

507.8

-2.01%↓

Search

Roche Holding AG

Chiusa

SettoreSettore sanitario

367.2 2.11

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

356.2

Massimo

367.2

Metriche Chiave

By Trading Economics

Entrata

1.8B

5.5B

Vendite

15B

31B

P/E

Media del settore

22.556

121.746

Rendimento da dividendi

2.7

Margine di Profitto

17.892

Dipendenti

103,249

EBITDA

1.5B

8B

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.70%

2.26%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1B

288B

Apertura precedente

365.09

Chiusura precedente

367.2

Notizie sul Sentiment di mercato

By Acuity

67%

33%

310 / 352 Classifica in Healthcare

Roche Holding AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 gen 2026, 10:07 UTC

Utili

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 gen 2026, 07:07 UTC

Utili

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18 nov 2025, 11:04 UTC

I principali Market Mover

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23 ott 2025, 09:32 UTC

Utili

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 ott 2025, 05:54 UTC

Utili

Roche Raises Full-Year Earnings Outlook

29 gen 2026, 11:40 UTC

Discorsi di Mercato
Utili

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 gen 2026, 06:05 UTC

Utili

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 gen 2026, 06:04 UTC

Utili

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 gen 2026, 06:03 UTC

Utili

Roche Issues 2026 View

29 gen 2026, 06:02 UTC

Utili

Analysts Saw 2025 Core EPS at CHF19.70

29 gen 2026, 06:02 UTC

Utili

Roche: 2025 Core EPS CHF19.46

29 gen 2026, 06:01 UTC

Utili

Analysts Had Seen 2025 Sales At CHF61.47B

29 gen 2026, 06:01 UTC

Utili

Roche 2025 Sales CHF61.52B

28 gen 2026, 11:22 UTC

Utili

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 gen 2026, 11:31 UTC

Discorsi di Mercato

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 gen 2026, 11:24 UTC

Discorsi di Mercato

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 gen 2026, 09:30 UTC

Discorsi di Mercato

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 gen 2026, 07:52 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Roche Obesity Study Data Look Encouraging -- Market Talk

16 gen 2026, 17:03 UTC

Discorsi di Mercato

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 gen 2026, 14:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Pharma Sector Can Spend Big on M&A -- Market Talk

22 dic 2025, 08:48 UTC

Discorsi di Mercato

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 nov 2025, 12:47 UTC

Discorsi di Mercato

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10 nov 2025, 12:16 UTC

Discorsi di Mercato
Utili

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23 ott 2025, 09:19 UTC

Discorsi di Mercato
Utili

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 ott 2025, 09:11 UTC

Discorsi di Mercato
Utili

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 ott 2025, 05:09 UTC

Utili

Roche 3Q Sales Up 6% At CER

23 ott 2025, 05:07 UTC

Utili

Roche 3Q Sales CHF14.92B

23 ott 2025, 05:07 UTC

Utili

Analysts Had Seen 3Q Sales At CHF15.17B

23 ott 2025, 05:07 UTC

Utili

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 ott 2025, 05:05 UTC

Utili

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

Confronto tra pari

Modifica del prezzo

Roche Holding AG Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

0

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

310 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat